{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"86"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"86"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"2"}],"units":"Participants"}],"description":"Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.","groups":[{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.\n\nTreatment Group A included solid tumors and lymphoma","id":"OG000","title":"Part1/Treatment Group A : 8mg QD INCB057643"},{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.\n\nTreatment Group A included solid tumors and lymphoma","id":"OG001","title":"Part1/Treatment Group A : 12mg QD INCB057643"},{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.\n\nTreatment Group A included solid tumors and lymphoma","id":"OG002","title":"Part1/Treatment Group A : 16mg QD INCB057643"},{"description":"Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF","id":"OG003","title":"Part1/Treatment Group B : 8mg QD INCB057643"},{"description":"Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF.","id":"OG004","title":"Part1/Treatment Group B : 12mg QD INCB057643"},{"description":"Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group C (TGC), based on protocol-specific criteria. Treatment Group C includes subjects with MM","id":"OG005","title":"Part1/Treatment Group C : 8mg QD INCB057643"},{"description":"Initial cohort dose of INCB054763 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group A (TGA), based on protocol-specific criteria. Part 2 Treatment Group A expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.","id":"OG006","title":"Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort"},{"description":"Initial cohort dose of INCB057463 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group B (TGB), based on protocol-specific criteria. Part 2 Treatment Group B expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.","id":"OG007","title":"Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort"},{"description":"Initial cohort dose of INCB057643 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Gemcitabine) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies where Gemcitabine is relevant","id":"OG008","title":"Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg"},{"description":"Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Paclitaxel) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.","id":"OG009","title":"Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg"},{"description":"Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Rucaparib) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.","id":"OG010","title":"Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg"},{"description":"Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Abiraterone + Prednisone) in Castration Resistant Prostrate Cancer","id":"OG011","title":"Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni"},{"description":"Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Ruxolitinib) in Myelofibrosis.","id":"OG012","title":"Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg"},{"description":"Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Azacitidine) in Acute Myeloid Leukemia and Myelodysplastic Syndrome","id":"OG013","title":"Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg"}],"paramType":"NUMBER","populationDescription":"All participants enrolled in the study who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From screening through at least 30 days after end of treatment, up to approximately 24 months","title":"Number of Participants With Treatment Emergent Adverse Events (TEAE's).","type":"PRIMARY","unitOfMeasure":"Participants"}